acon stock: Aclarion, Inc. (ACON) Overview
Aclarion, Inc. (ACON)
acon stock refers to the publicly traded equity ticker ACON for Aclarion, Inc., a small-cap medical‑software company focused on MR spectroscopy analysis and spine imaging decision support. This entry summarizes the company profile, NOCISCAN product suite, clinical programs, corporate history, market data and reported risks — and points readers to official filings and market feeds for verification.
Company overview
Aclarion, Inc. operates in the health information services and medical imaging software sector, developing MR spectroscopy analysis tools for spine and intervertebral disc assessment. Headquartered in Broomfield, Colorado (per corporate filings), the company offers software-as-a-service solutions marketed primarily to imaging centers, radiology groups and spine clinicians.
acon stock (ticker ACON) is the company’s U.S.-listed equity. As of 2026-01-25, according to Nasdaq and Yahoo Finance reporting, Aclarion is widely characterized as a micro-cap/small-cap issuer with limited trading liquidity.
Products and services
NOCISCAN suite
The NOCISCAN platform is Aclarion’s flagship MR spectroscopy analysis product. NOCISCAN produces quantitative biomarkers to assist clinicians assessing discogenic pain and spine pathology. Named modules (reported in company materials) include automated report generation and clinical decision support components such as NOCIGRAM and NOCICALC to standardize outputs for referring physicians.
Other offerings and delivery model
Aclarion provides a cloud-based SaaS delivery model with AI/quality-control elements embedded in workflow. Revenue is driven by scan reporting fees, software subscriptions and clinical partnerships.
Clinical programs and research
Aclarion has publicized clinical registries and trials (including a CLARITY trial referenced in company announcements). As of 2026-01-25, company press releases and market summaries report early site enrollments and conference presentations of MR spectroscopy biomarkers in peer-reviewed venues. Readers should consult trial registries and peer-reviewed publications for primary clinical evidence.
Corporate history and timeline
Founded to commercialize NOCISCAN technology, Aclarion has undergone financing rounds, leadership appointments and name/branding updates in its corporate history. Material corporate developments are disclosed via SEC filings and company press releases.
Public listing and market information
Ticker and exchange
ACON is quoted on Nasdaq. Traders and investors refer to this symbol when tracking acon stock.
Trading characteristics
acon stock is commonly described as a micro-cap with thin liquidity and variable daily volume. As of 2026-01-25, market-data providers note low average trading volumes and a highly variable share price.
Price history and notable data
Market pages report a wide 52‑week range for acon stock (examples cited by market sites include roughly $6.20 to $3,499.51). Such extreme ranges may reflect thin float, reporting anomalies, or corporate actions (reverse splits, symbol history); verify via exchange notices and SEC disclosures.
Financial overview
Public sources report limited revenue, negative earnings and a market capitalization described as being in the low millions. For audited financial statements, cash position, liabilities and revenue breakdown, consult the company’s latest 10‑Q/10‑K on EDGAR.
Corporate governance and management
Board and executive appointments are listed in company filings and investor materials. Recent management changes and CFO appointments have been announced in press releases; for current officer listings, refer to investor relations.
Investors, ownership and capital activity
Filings disclose insider holdings, any institutional positions and equity financing events. Company press releases and SEC forms record securities purchase agreements and dilution events when material.
Regulatory, legal and compliance matters
As a medical-technology firm, regulatory oversight of clinical trials, IRB approvals and claims about clinical effectiveness are material. No widespread regulatory enforcement or major litigation is reported publicly in market summaries as of 2026-01-25; check 8‑K/10‑Q filings for disclosures.
Risks and market considerations
Key risks for acon stock include micro‑cap volatility, thin liquidity, limited operating revenue, reliance on clinical validation and potential reporting anomalies in quoted price ranges. Market participants should verify reported figures and company disclosures before forming opinions.
Recent news and developments
As of 2026-01-25, multiple market-data sites (Nasdaq, Yahoo Finance, Reuters) report company press releases on CLARITY trial enrollment progress, management updates and financing activities. For the most current announcements, consult the company news feed and SEC filings.
See also
- Magnetic resonance spectroscopy
- Clinical decision support software
- List of medical imaging companies
- Micro-cap stock characteristics
References
- Company investor relations materials and SEC filings (EDGAR)
- Market-data summaries: Yahoo Finance, Nasdaq, CNBC, Reuters (reported 2026-01-25)
- Analyst and news coverage: Morningstar, SoFi, CNN Markets, Stocktwits (market pages used for trading data and social sentiment)
External links
- Company website (investor relations and product pages)
- SEC filings (EDGAR)
Further exploration: verify acon stock price and filings on official market feeds and EDGAR, and consider tracking trading access and advanced tools on Bitget to follow market activity and manage alerts.
